NICE 'conditional approvals' to replace England's Cancer Drugs Fund
This article was originally published in Scrip
Executive Summary
A new "managed access fund" for financing oncology drugs conditionally approved by NICE could provide a proper long-term remedy to England's poor uptake of oncology products if it can replace the Cancer Drugs Fund, something that has become a soggy sticking plaster. But although the plans may offer companies hope of market access for future drugs, there is still uncertainty over what will happen to patients and drugs failed by the current system, like Eisai's Halaven.